Home
Site Map
Contact Us
Graphics Version
Printer Version
Main Navigation
ABOUT US
COMPANY PROFILE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
STRATEGY
Recent
2007
2006
2005
2004
2003
2002
2001
2000
MANAGEMENT TEAM
Recent
2007
2006
2005
2004
2003
2002
2001
2000
BOARD OF DIRECTORS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SCIENTIFIC ADVISORY BOARD
Recent
2007
2006
2005
2004
2003
2002
2001
2000
CONTACT US
Recent
2007
2006
2005
2004
2003
2002
2001
2000
THERAPEUTIC FOCUS
CARDIOVASCULAR
Recent
2007
2006
2005
2004
2003
2002
2001
2000
CNS
Huntington's Disease
Myasthenia Gravis
Parkinson's Disease
Epilepsy
PRODUCTS
PIPELINE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 for Hypertriglyceridemia
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 for HD
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 for AAMI
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EN101
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SUBLINGUAL APOMORPHINE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
NASAL LORAZEPAM
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AMR103
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SCIENCE & TECHNOLOGY
INTRODUCTION
Lipophilic Platform
Targeted Lipid Transport Technology Platform
Cholinergic Platform
PARTNERING
PARTNERING
Recent
2007
2006
2005
2004
2003
2002
2001
2000
STRATEGIC ALLIANCES
Recent
2007
2006
2005
2004
2003
2002
2001
2000
BUSINESS DEVELOPMENT
Recent
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
Recent
2007
2006
2005
2004
2003
2002
2001
2000
STOCK INFORMATION
Recent
2007
2006
2005
2004
2003
2002
2001
2000
CORPORATE GOVERNANCE
AUDIT COMMITTEE
REMUNERATION COMMITTEE
LEAD INDEPENDENT DIRECTOR
CODE OF ETHICS
MEMORANDUM AND ARTICLES OF ASSOCIATION
PRESENTATIONS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
PRESS RELEASES
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR FAQ
Recent
2007
2006
2005
2004
2003
2002
2001
2000
FINANCIAL REPORTS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SEC FILINGS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AGM 2008
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EGM 2008
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AGM 2007
Recent
2007
2006
2005
2004
2003
2002
2001
2000
ANALYST COVERAGE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EMAIL ALERTS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
REQUEST INFORMATION
Recent
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
STOCK INFORMATION
CORPORATE GOVERNANCE
PRESENTATIONS
PRESS RELEASES
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
INVESTOR FAQ
FINANCIAL REPORTS
SEC FILINGS
AGM 2008
EGM 2008
AGM 2007
ANALYST COVERAGE
EMAIL ALERTS
REQUEST INFORMATION
Mailing List
Join our mailing list if you wish to receive updates by email
Mailing List
Unsubscribe »
INVESTOR
RELATIONS
PRESS RELEASES
11-Nov-2004
AMARIN CORPORATION REPORTS THIRD QUARTER 2004 FINANCIAL RESULTS
12-Oct-2004
AMARIN CORPORATION CLOSES ACQUISITION OF LAXDALE LTD.
7-Oct-2004
AMARIN CORPORATION RAISES $12.75 MILLION IN PRIVATE PLACEMENT OF ORDINARY SHARES
1-Oct-2004
AMARIN ANNOUNCES PURCHASE BY CHAIRMAN OF EQUITY AND DEBT INTERESTS IN AMARIN FROM ELAN
29-Sep-2004
AMARIN CORPORATION ANNOUNCES RESOLUTION OF VALEANT DISPUTE
28-Sep-2004
AMARIN SHAREHOLDERS APPROVE ACQUISITION OF LAXDALE LIMITED
24-Aug-2004
AMARIN CORPORATION ANNOUNCES RESULTS OF GENE VARIANT DATA ANALYSIS FROM INITIAL MIRAXION™ PHASE III CLINICAL TRIAL
29-Jul-2004
AMARIN CORPORATION REPORTS SECOND QUARTER 2004 FINANCIAL RESULTS
12-Jul-2004
AMARIN CORPORATION ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE LAXDALE LTD.
12-May-2004
AMARIN CORPORATION REPORTS FIRST QUARTER 2004 FINANCIAL RESULTS
25-Mar-2004
AMARIN CORPORATION REPORTS FOURTH QUARTER AND YEAR-END 2003 FINANCIAL RESULTS
1-Mar-2004
RESIGNATION OF AMARIN OFFICERS FOLLOWING ASSET SALE TO VALEANT PHARMACEUTICALS INTERNATIONAL
26-Feb-2004
AMARIN CORPORATION COMPLETES ASSET SALE TO VALEANT PHARMACEUTICALS INTERNATIONAL
12-Feb-2004
AMARIN CORPORATION ANNOUNCES SETTLEMENT OF FINANCIAL OBLIGATIONS TO ELAN
12-Feb-2004
AMARIN CORPORATION ANNOUNCES ASSET SALE TO VALEANT PHARMACEUTICALS INTERNATIONAL
2-Feb-2004
AMARIN CORPORATION ANNOUNCES LETTER OF INTENT TO SELL CERTAIN ASSETS TO VALEANT PHARMACEUTICALS INTERNATIONAL
Website Design and Development by Webtrade.ie